Advisory Committee Member Viewpoints On Meeting Topics Should Be Part Of Vetting Process, GAO Says
This article was originally published in The Pink Sheet Daily
Collecting information on committee member viewpoints ensures independence and impartiality in public eye, GAO report states. Committee nominees should be asked about public statements, participation in legal proceedings, previous research, GAO adds.
You may also be interested in...
Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.